Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Pleuropulmonary blastoma 1Neurofibrosarcoma 1Neuroblastoma 1

Interventions

X-Rays 5Phantoms, Imaging 5Magnetic Resonance Spectroscopy 5Specimen Handling 4Nuclear Medicine Department, Hospital 4Melphalan 4Granulocyte Colony-Stimulating Factor 4Busulfan 4Filgrastim 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2fludarabine 2ensartinib 2cabozantinib 2Vemurafenib 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Sirolimus 2Mesna 2LY3023414 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × lorvotuzumab mertansine × Genitourinary × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡